| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/17425247.2014.927439 |
| P8608 | Fatcat ID | release_jf4ba4hjyvev5fhvo46gnxko4q |
| P698 | PubMed publication ID | 24950005 |
| P5875 | ResearchGate publication ID | 263289278 |
| P50 | author | Xianghui Zeng | Q48216738 |
| Stefano Colombo | Q49380798 | ||
| Héloïse Ragelle | Q99714469 | ||
| Camilla Foged | Q41637299 | ||
| P2860 | cites work | Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy | Q21223673 |
| Understanding biophysicochemical interactions at the nano-bio interface | Q23909863 | ||
| Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs | Q24299641 | ||
| Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA | Q24316383 | ||
| Improved targeting of miRNA with antisense oligonucleotides | Q24547511 | ||
| Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality | Q24794430 | ||
| Functional polarity is introduced by Dicer processing of short substrate RNAs | Q24814800 | ||
| Nucleic acid delivery: the missing pieces of the puzzle? | Q26851886 | ||
| Argonaute2 is the catalytic engine of mammalian RNAi | Q27860545 | ||
| RNA interference is mediated by 21- and 22-nucleotide RNAs | Q27860764 | ||
| Role for a bidentate ribonuclease in the initiation step of RNA interference | Q27860832 | ||
| Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans | Q27860867 | ||
| Silencing of microRNAs in vivo with 'antagomirs' | Q27860891 | ||
| Pattern recognition receptors and inflammation | Q27861115 | ||
| Progress toward in vivo use of siRNAs-II | Q28255877 | ||
| Strategies for silencing human disease using RNA interference | Q28288535 | ||
| Assessing the relevance of in vitro studies in nanotoxicology by examining correlations between in vitro and in vivo data | Q28384334 | ||
| What the Cell “Sees” in Bionanoscience | Q28651814 | ||
| Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts | Q28651929 | ||
| Profound effect of profiling platform and normalization strategy on detection of differentially expressed microRNAs--a comparative study | Q28728292 | ||
| RNA Interference and Cancer Therapy | Q29392204 | ||
| RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals | Q29547713 | ||
| Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology | Q29615485 | ||
| Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles | Q29615957 | ||
| Expression profiling reveals off-target gene regulation by RNAi | Q29615965 | ||
| Single processing center models for human Dicer and bacterial RNase III | Q29618466 | ||
| A rapid and sensitive method to detect siRNA-mediated mRNA cleavage in vivo using 5' RACE and a molecular beacon probe | Q33633775 | ||
| Surface engineered Poly(lactide-co-glycolide) nanoparticles for intracellular delivery: uptake and cytotoxicity--a confocal raman microscopic study | Q33706515 | ||
| Systematic evaluation of three microRNA profiling platforms: microarray, beads array, and quantitative real-time PCR array | Q33828375 | ||
| Protection and Systemic Translocation of siRNA Following Oral Administration of Chitosan/siRNA Nanoparticles. | Q33902729 | ||
| Pharmaceutical nanotechnology: more than size. Ten topics for research | Q47281883 | ||
| Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering | Q47348681 | ||
| Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. | Q48530108 | ||
| Emerging techniques for submicrometer particle sizing applied to Stöber silica. | Q48782951 | ||
| Sizing nanomatter in biological fluids by fluorescence single particle tracking. | Q49087618 | ||
| Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. | Q51562160 | ||
| Asymmetric RNA duplexes mediate RNA interference in mammalian cells. | Q53436494 | ||
| Enhancement of RNAi activity by improved siRNA duplexes. | Q54732681 | ||
| Detailed Identification of Plasma Proteins Adsorbed on Copolymer Nanoparticles | Q55167507 | ||
| Comparison of four different particle sizing methods for siRNA polyplex characterization | Q39534238 | ||
| The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls | Q39644429 | ||
| Stem-loop RT-PCR quantification of siRNAs in vitro and in vivo. | Q39873412 | ||
| Modifications in small interfering RNA that separate immunostimulation from RNA interference | Q40010193 | ||
| Cellular dynamics of EGF receptor-targeted synthetic viruses. | Q40141493 | ||
| RNA interference from multimeric shRNAs generated by rolling circle transcription | Q40199287 | ||
| The internalization route resulting in successful gene expression depends on both cell line and polyethylenimine polyplex type | Q40231070 | ||
| Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes | Q40407997 | ||
| Quantitative detection of siRNA and single-stranded oligonucleotides: relationship between uptake and biological activity of siRNA. | Q40485384 | ||
| Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3'-ends of siRNAs | Q40684099 | ||
| Lipoplex nanostructures reveal a general self-organization of nucleic acids | Q41621270 | ||
| Medical ethics. Principles for human gene therapy studies | Q41727720 | ||
| Characterization of submicron systems via optical methods | Q41728245 | ||
| Structural insights into mRNA recognition from a PIWI domain-siRNA guide complex | Q42184881 | ||
| Size influences the cytotoxicity of poly (lactic-co-glycolic acid) (PLGA) and titanium dioxide (TiO(2)) nanoparticles. | Q42626462 | ||
| Nanotoxicology: in vitro-in vivo dosimetry | Q43059106 | ||
| Impact of normalization on miRNA microarray expression profiling | Q43161221 | ||
| Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel | Q43287891 | ||
| Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes | Q43923118 | ||
| After 40 years, fate of recombinant DNA committee under review | Q44312719 | ||
| Intracellular dynamics of the gene delivery vehicle polyethylenimine during transfection: investigation by two-photon fluorescence correlation spectroscopy | Q44668463 | ||
| Studying the protein corona on nanoparticles by FCS. | Q45794209 | ||
| Differential analysis of "protein corona" profile adsorbed onto different nonviral gene delivery systems | Q45872743 | ||
| The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. | Q45977543 | ||
| Pore-forming peptides induce rapid phospholipid flip-flop in membranes. | Q46016360 | ||
| In vivo SPECT and real-time gamma camera imaging of biodistribution and pharmacokinetics of siRNA delivery using an optimized radiolabeling and purification procedure | Q46191778 | ||
| Statistical analysis of nanoparticle dosing in a dynamic cellular system | Q46540742 | ||
| Quantitation of phosphorothioate oligonucleotides in human plasma | Q46550655 | ||
| Chemically modified symmetric and asymmetric duplex RNAs: an enhanced stability to nuclease degradation and gene silencing effect. | Q46923203 | ||
| Endocytosis of nanomedicines. | Q33987301 | ||
| Mutations that lead to reiterations in the cell lineages of C. elegans | Q34282331 | ||
| First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement | Q34324970 | ||
| Unlocking the potential of the human genome with RNA interference | Q34348958 | ||
| Quantitative evaluation of siRNA delivery in vivo. | Q34370185 | ||
| Cationic lipids enhance siRNA-mediated interferon response in mice. | Q34408761 | ||
| Dicing and slicing: the core machinery of the RNA interference pathway | Q34458132 | ||
| Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways | Q34530552 | ||
| Cyclodextrin-based pharmaceutics: past, present and future | Q34552997 | ||
| A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy | Q34558019 | ||
| Time evolution of nanoparticle-protein corona in human plasma: relevance for targeted drug delivery. | Q34696294 | ||
| Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 | Q34764750 | ||
| In search of the most relevant parameter for quantifying lung inflammatory response to nanoparticle exposure: particle number, surface area, or what? | Q35695431 | ||
| About the nature of RNA interference | Q36036766 | ||
| MicroRNA targeting in mammalian genomes: genes and mechanisms | Q36189275 | ||
| The therapeutic potential of RNA interference | Q36237868 | ||
| Small RNA asymmetry in RNAi: function in RISC assembly and gene regulation. | Q36274428 | ||
| Cationic amphipathic histidine-rich peptides for gene delivery. | Q36422346 | ||
| On the art of identifying effective and specific siRNAs | Q36575382 | ||
| Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells | Q36603910 | ||
| Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy | Q36698269 | ||
| Factors affecting the clearance and biodistribution of polymeric nanoparticles. | Q37146591 | ||
| Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth | Q37182706 | ||
| Chemical modification of siRNAs for in vivo use. | Q37331765 | ||
| Biological barriers to therapy with antisense and siRNA oligonucleotides | Q37378340 | ||
| Knocking down barriers: advances in siRNA delivery | Q37380671 | ||
| Absolute quantification of microRNAs by using a universal reference | Q37426569 | ||
| Nanocarriers' entry into the cell: relevance to drug delivery | Q37508725 | ||
| Cationic carriers of genetic material and cell death: a mitochondrial tale. | Q37728359 | ||
| Strategies for in vivo delivery of siRNAs: recent progress | Q37749809 | ||
| Strategies for the intracellular delivery of nanoparticles | Q37795605 | ||
| Endosomal escape pathways for delivery of biologicals | Q37809596 | ||
| Bioanalysis of siRNA and oligonucleotide therapeutics in biological fluids and tissues | Q37810190 | ||
| Physical and chemical stability of drug nanoparticles | Q37840489 | ||
| Neuronal receptors that regulate axon growth | Q37843922 | ||
| Aggregation in colloidal suspensions: effect of colloidal forces and hydrodynamic interactions. | Q37885530 | ||
| Material properties in complement activation | Q37892097 | ||
| Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention | Q37905250 | ||
| In vivo biodistribution of nanoparticles | Q37906630 | ||
| Using drug-excipient interactions for siRNA delivery | Q37938423 | ||
| Physicochemical characterization techniques for lipid based delivery systems for siRNA. | Q37943155 | ||
| Reshaping the future of nanopharmaceuticals: ad iudicium. | Q37944864 | ||
| Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design | Q37949042 | ||
| Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment | Q37956582 | ||
| Genomic perspectives in inter-individual adverse responses following nanomedicine administration: The way forward | Q38013471 | ||
| Cationic liposome/DNA complexes: from structure to interactions with cellular membranes. | Q38019777 | ||
| Attacking the genome: emerging siRNA nanocarriers from concept to clinic | Q38021047 | ||
| Safety profile of RNAi nanomedicines | Q38021607 | ||
| Polycation-based nanoparticle delivery of RNAi therapeutics: adverse effects and solutions | Q38026631 | ||
| Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery | Q38090525 | ||
| Endocytosis of gene delivery vectors: from clathrin-dependent to lipid raft-mediated endocytosis | Q38099153 | ||
| History of gene therapy | Q38101761 | ||
| Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. | Q38106032 | ||
| Polysaccharide-based nucleic acid nanoformulations. | Q38107310 | ||
| Chitosan-based siRNA delivery systems | Q38130561 | ||
| Delivery materials for siRNA therapeutics | Q38154803 | ||
| RNA-induced silencing complex-bound small interfering RNA is a determinant of RNA interference-mediated gene silencing in mice. | Q38336470 | ||
| Quantitation of phosphorothioate oligonucleotides in human blood plasma using a nanoparticle-based method for solid-phase extraction | Q38336672 | ||
| A competitive enzyme hybridization assay for plasma determination of phosphodiester and phosphorothioate antisense oligonucleotides | Q38343152 | ||
| A direct comparison of anti-microRNA oligonucleotide potency. | Q38344485 | ||
| Toxicity of surface-modified PLGA nanoparticles toward lung alveolar epithelial cells. | Q39142411 | ||
| Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface | Q39207806 | ||
| Evaluation of carrier-mediated siRNA delivery: lessons for the design of a stem-loop qPCR-based approach for quantification of intracellular full-length siRNA. | Q39211677 | ||
| Size of TiO(2) nanoparticles influences their phototoxicity: an in vitro investigation. | Q39299090 | ||
| Tuning nanoparticle uptake: live-cell imaging reveals two distinct endocytosis mechanisms mediated by natural and artificial EGFR targeting ligand | Q39342064 | ||
| MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model | Q39349493 | ||
| Impact of delivery systems on siRNA immune activation and RNA interference | Q39457836 | ||
| Biodegradable nanoparticles meet the bronchial airway barrier: how surface properties affect their interaction with mucus and epithelial cells. | Q39461680 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1481-1495 | |
| P577 | publication date | 2014-06-20 | |
| P1433 | published in | Expert Opinion on Drug Delivery | Q5421203 |
| P1476 | title | Complexity in the therapeutic delivery of RNAi medicines: an analytical challenge | |
| P478 | volume | 11 |
| Q45826092 | Atelocollagen-mediated in vivo siRNA transfection in ovarian carcinoma is influenced by tumor site, siRNA target and administration route. |
| Q41042177 | Human DMBT1-Derived Cell-Penetrating Peptides for Intracellular siRNA Delivery |
| Q35846800 | Inhibition of myeloid differentiation factor 88 signaling mediated by histidine-grafted poly(β-amino ester) ester nanovector induces donor-specific liver allograft tolerance. |
| Q53027947 | Manufacturing DTaP-based combination vaccines: industrial challenges around essential public health tools. |
| Q27002403 | Oligonucleotide Therapies: The Past and the Present |
| Q42700665 | Potential applications of MEG3 in cancer diagnosis and prognosis |
| Q38820640 | Surface coating of siRNA-peptidomimetic nano-self-assemblies with anionic lipid bilayers: enhanced gene silencing and reduced adverse effects in vitro |
| Q90129514 | The Landscape of Early Clinical Gene Therapies outside of Oncology |
| Q97072562 | The role of Long Non-Coding RNAs (lncRNAs) and downstream signaling pathways in Leukemia progression |
Search more.